Clinical Trial Search

Primary: Overall Response Rate (ORR) — 7.1 percentage of participants

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Participants With a Clinical Response — 0 Participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Complete Response Rate — 10 percentage of participants

Primary: Phase I: Maximum Tolerated Dose (MTD) — NA mg

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Overall Objective Response — 10; 5; 26; 4 Participants

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants With Complete Remission (CR) — 185 Participants

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 — 8.1; NA months — p=<0.0001

Primary: Number of Subjects With Adverse Events — 199 Participants

Primary: Overall Response Rate — 6; 7 Participants

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Best Response — 20; 3; 3 Participants

Primary: Response Rate — 11; 6 participants

Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Overall Response — 11; 23; 4; 5 participants